Satsuma Pharmaceuticals, Inc. STSA
We take great care to ensure that the data presented and summarized in this overview for Satsuma Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in STSA
Top Purchases
Top Sells
About STSA
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Insider Transactions at STSA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 08
2023
|
Ra Capital Management, L.P. |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
5,914,252
-100.0%
|
-
|
|
Jun 08
2023
|
Shin Nippon Biomedical Laboratories, Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
8,423,732
+50.0%
|
$0
$0.91 P/Share
|
|
Jun 06
2023
|
Rajeev M. Shah Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
5,914,252
-100.0%
|
$0
$0.91 P/Share
|
|
Jun 06
2023
|
Thomas P. O'Neil Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
13,877
-100.0%
|
$0
$0.91 P/Share
|
|
Jun 06
2023
|
Ken Takanashi Director |
BUY
Open market or private purchase
|
Indirect |
22,053,581
+47.02%
|
$0
$0.91 P/Share
|
|
Jun 06
2023
|
John A Kollins President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
305,911
-100.0%
|
$0
$0.91 P/Share
|
|
Jun 06
2023
|
Shin Nippon Biomedical Laboratories, Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
22,053,581
+50.0%
|
$0
$0.91 P/Share
|
|
Nov 21
2022
|
Braden Michael Leonard > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
150,000
+50.0%
|
$0
$0.71 P/Share
|
|
Nov 15
2022
|
Braden Michael Leonard > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
831,694
+6.21%
|
$0
$0.63 P/Share
|
|
Nov 14
2022
|
Braden Michael Leonard > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
5,608,306
+50.0%
|
$0
$0.69 P/Share
|
|
Nov 14
2022
|
Commodore Capital LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,250,000
-87.57%
|
$0
$0.71 P/Share
|
|
Nov 24
2021
|
Commodore Capital LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,922
+0.08%
|
$14,610
$5.42 P/Share
|
|
Nov 22
2021
|
Commodore Capital LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
9,979
+0.27%
|
$49,895
$5.49 P/Share
|
|
Nov 19
2021
|
Commodore Capital LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
3,225
+0.09%
|
$16,125
$5.44 P/Share
|
|
Nov 11
2021
|
Commodore Capital LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
7,941
+0.21%
|
$47,646
$6.05 P/Share
|
|
Nov 10
2021
|
Commodore Capital LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
9,622
+0.26%
|
$48,110
$5.85 P/Share
|
|
Nov 08
2021
|
Commodore Capital LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
560
+0.02%
|
$2,800
$5.99 P/Share
|
|
Nov 05
2021
|
Commodore Capital LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
7,800
+0.21%
|
$39,000
$5.95 P/Share
|
|
Nov 04
2021
|
Commodore Capital LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,400
+0.04%
|
$7,000
$5.88 P/Share
|
|
Nov 02
2021
|
Commodore Capital LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
8,880
+0.24%
|
$44,400
$5.64 P/Share
|